Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations.
Redeye is encouraged by the new management in Sivers, guiding for a long-term ambition of reaching a...
Redeye comments on Better Collective’s Q3-results which were in line with the preliminary announceme...
Redeye somewhat cuts its forecasts and Base Case following a Q3 with soft ARR growth yet lower OPEX ...
Redeye provides an update on Scandinavian ChemoTech following the Q3 2024 report.
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 13 november år 2024 att samtliga patienter har gen...
Redeye is favourable to InfraCom’s Q3 2024 report, which resulted in the stock rallying 9%, although...
Nu är guldproduktionen i Fäbodtjärn i gång. Gruvan invigdes i maj och i augusti sköts den första mal...
Redeye sees a Q3 report from BrightBid on the soft side regarding ARR growth.
Redeye has updated its estimates and valuation following Physitrack’s Q3 report.
Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Te...
Higher sales and gross margin in Q3 EBIT revised up 12.
Redeye comments on Scandion Oncology’s Q3 2024 report, and we judge a potential partnership or simil...
Redeye saw a Q3 report showing sales above our estimates, with a total growth of 16% for the quarter...
Redeye shares its initial take on Physitrack’s Q3 results, which were generally in line with our mod...
